NCT07116174View on ClinicalTrials.gov

A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Different Wound Types

NANot yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

August 15, 2026

Study Completion Date

August 15, 2026

Conditions
Diabetic Foot Ulcer (DFU)Venous Leg Ulcer (VLU)Post-Mohs Surgical Wound
Interventions
BIOLOGICAL

Xcell Amnio Matrix

A lyophilized amniotic membrane allograft

Sponsors

Collaborators (1)

Amarex Clinical Research
All Listed Sponsors
collaborator

Amarex Clinical Research

OTHER

lead

New Horizon Medical Solutions

NETWORK

NCT07116174 - A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Different Wound Types | Biotech Hunter | Biotech Hunter